Earlier this week, the FDA issued new warning labels to Procrit, Epogen, and Aranesp. These drugs are used to increase hemoglobin levels in patients with chronic renal failure and cancer. Changes to the warnings for patients with cancer include a risk of shortened survival and tumor progression when the dosage reaches a certain level. The warning changes for patients with chronic renal failure include removing claims of improved qualitify of life. To read more about these changes visit this site.
For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.